16 Nov SIMPLAAFY Trial: Simpler Antithrombotic Regimens After WATCHMAN FLX Pro Left Atrial Appendage Closure
Health Notice: The aspirin-only and reduced-dose NOAC regimens discussed in this interview are investigational and are not part of the current device labeling. Antiplatelet and anticoagulant medications should only be prescribed, adjusted or stopped by your healthcare provider. Never change or stop blood-thinning medication on your own. This interview is for educational purposes and is not medical advice.
Editorial Notice: The interviewee is an employee of Boston Scientific, the manufacturer of the WATCHMAN FLX Pro device and the sponsor of the SIMPLAAFY trial. Products and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Dr. Brad Sutton, MD[/caption]
MedicalResearch.com Interview with:
Dr. Brad Sutton, M.D.
Chief Medical Officer, AF Solutions
Boston Scientific
Antithrombotic Therapy After Left Atrial Appendage Occlusion: The SIMPLAAFY Randomized Clinical Trial
MedicalResearch.com: What is the background for this study? Would you briefly explain what the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device is indicated for?
Response: The SIMPLAAFY randomized controlled trial is evaluating whether simplified antithrombotic regimens following implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device can reduce bleeding risk while providing effective protection against device-related blood clots in patients with non-valvular atrial fibrillation (NVAF). While dual antiplatelet therapy (DAPT) helps prevent clotting as the heart tissue heals over the device, it also carries a risk of bleeding. The trial is comparing the safety and efficacy of on-label DAPT with two investigational monotherapy regimens: aspirin alone for the 12-month duration of the trial or reduced-dose non-vitamin K antagonist oral anticoagulant (NOAC) for the first three months followed by aspirin only. The six-month results were presented at the 2026 TCT Conference and simultaneously published in JAMA.
The WATCHMAN FLX Pro LAAC Device is designed to reduce stroke risk by closing the left atrial appendage, where stroke-causing blood clots can form in patients with NVAF. It represents an alternative approach to long-term oral anticoagulation for eligible patients who are at increased risk of stroke, are suitable for anticoagulation therapy and have an appropriate reason to seek a non-drug alternative. Patients with NVAF who have undergone prior cardiac ablation may also be eligible without needing a separate rationale for avoiding long-term anticoagulation. The device also features HEMOCOAT™ Technology, designed to promote faster, more controlled healing after implantation.
Dr. Singer[/caption]
Daniel E. Singer, MD
Professor of Medicine, Harvard Medical School
Professor in the Department of Epidemiology
Harvard T.H. Chan School of Public Health
Division of General Internal Medicine
Massachusetts General Hospital
Boston, MA, 02114
MedicalResearch.com: What is the background for this study?
Response: Atrial fibrillation (AF) raises the risk of ischemic stroke 4-5-fold and this risk is largely reversible by oral anticoagulants (OAC). These facts are part of the core knowledge of internal medicine and the basis of multiple guidelines. They are based on studies of patients with persistent or predominantly “heavy burden” paroxysmal AF completed in the 1990s.
More recent studies using cardiac implantable devices (CIEDs: implantable defibrillators, pacemakers, etc) which have the capacity to monitor heart rhythm continuously have found that many older patients have brief, often undiagnosed, episodes of AF. Several of these studies have found that strokes occur during periods of sinus rhythm temporally distant from a preceding episode of AF. This has led to a widespread suspicion that AF is not a direct causal risk factor but a risk “marker” indicating the presence of other truly causal features like a diseased left atrium (atrial myopathy). If the risk marker hypothesis is correct, then long-term anticoagulation is needed even for brief and rare episodes of AF (assuming the patient’ s CHA2DS2-VASc score is high enough). The key problem with prior prospective studies using CIEDs was that only a small number of strokes were observed leading to inadequate statistical power.
Our study addressed this power problem by linking the very large Optum electronic health record database which could identify ischemic strokes with the Medtronic CareLink database of long-term, continuous heart rhythm records of patients with CIEDs. We ended up studying 891 individuals who had an ischemic stroke and had 120 days of continuous heart monitoring prior to the stroke.